4月29日，泰凌医药(01011)盘中下跌8.62%，截至09:54，报0.53元/股，成交954.43万元。
中国泰凌医药集团有限公司主要以分销国内外制造商生产的超过19种疫苗为主，占据中国Ⅱ类疫苗市场份额23.4%，并与多家国际大型医药企业有紧密合作关系。随着公司策略调整，目前已转变为一家以骨科、精神、肝病和肿瘤药物研发、生产、销售为一体的综合性医药企业，专注于骨病治疗领域，将于2023年创新打造“专业骨病健康平台”。
截至2024年年报，泰凌医药营业总收入3796.0万元、净利润-5335.7万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.